vaccin
repres
one
greatest
contribut
scientif
commun
global
health
yet
mani
pathogen
remain
either
unchalleng
inadequ
hinder
commerci
avail
vaccin
respiratori
virus
pose
distinct
difficult
challeng
due
abil
rapidli
spread
adapt
modifi
host
immun
respons
consider
research
direct
understand
role
respiratori
viru
immunomodulatori
protein
influenc
host
immun
respons
review
effort
develop
nextgener
vaccin
target
key
immunomodulatori
gene
influenza
viru
coronavirus
respiratori
syncyti
viru
measl
viru
mump
viru
much
past
centuri
vaccin
develop
focus
direct
attenu
inactiv
pathogen
approach
albeit
quit
success
larg
number
human
pathogen
complet
amen
effect
vaccin
must
follow
properti
high
immunogen
abl
induc
last
memori
genet
stabl
physic
thermal
stabl
importantli
safe
find
proper
balanc
properti
proven
quit
difficult
develop
effect
vaccin
prepar
mani
respiratori
virus
though
effect
histor
success
vaccin
current
exist
sever
respiratori
virus
efficaci
sever
current
vaccin
margin
remain
unmet
need
mani
respiratori
virus
liveattenu
vaccin
long
histori
success
gener
immunogen
nonrepl
vaccin
type
due
persist
antigen
mimic
infect
howev
classic
attenu
process
serial
passag
lengthi
may
challeng
achiev
proper
balanc
safeti
potenc
possibl
revers
compensatori
mutat
mani
current
effort
design
liveattenu
vaccin
focus
way
suppress
nonstructur
immunomodulatori
protein
respiratori
virus
genet
stabl
genet
modif
delet
codon
deoptim
major
advantag
approach
permit
recoveri
genet
stabl
infecti
viru
often
attenu
boost
immun
respons
review
effort
target
immunomodulatori
gene
toward
design
next
gener
liveattenu
vaccin
influenza
viru
coronavirus
respiratori
syncyti
viru
measl
viru
mump
viru
influenza
virus
pleomorph
envelop
virus
encod
singlestrand
negativesens
segment
rna
genom
influenza
virus
remain
one
preval
respiratori
pathogen
circul
respons
million
death
annual
spanish
flu
pandem
result
mani
million
death
worldwid
highlight
potenti
viru
highli
pathogen
caus
sever
diseas
three
primari
serotyp
base
genet
variat
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
influenza
iav
influenza
b
ibv
influenza
c
icv
current
influenza
vaccin
prepar
consist
either
inactiv
liveattenu
trival
quadrival
prepar
antigen
two
iav
either
one
two
ibv
strain
icv
far
less
common
iav
ibv
associ
mild
diseas
howev
season
variat
due
varieti
factor
includ
genet
drift
incongru
antigen
vaccin
domin
strain
within
flu
season
result
margin
efficaci
influenza
vaccin
best
need
annual
vaccin
avail
immunogen
liveattenu
influenza
vaccin
option
open
door
potenti
genet
modif
may
improv
durat
efficaci
protect
immun
despit
exist
vaccin
continu
effort
made
continu
improv
influenza
vaccin
design
incorpor
better
understand
viru
relationship
host
genom
influenza
consist
negativestrand
segment
encod
least
protein
potenti
sever
addit
protein
variant
due
ribosom
frameshift
altern
splice
truncat
identifi
figur
segment
ha
np
na
monocistron
known
code
altern
splice
truncat
protein
variant
segment
encod
subunit
viral
polymeras
also
known
translat
coupl
protein
variant
ntermin
truncat
call
altern
splice
protein
segment
pa
encod
addit
subunit
viral
polymeras
complex
known
express
least
three
altern
form
includ
protein
call
pax
form
via
ribosom
frameshift
addit
segment
encod
two
protein
variant
segment
encod
protein
function
packagingassembl
format
proton
ion
channel
import
multipl
phase
viru
cycl
respect
segment
encod
nonstructur
protein
function
directli
host
cell
modul
varieti
mechan
repres
primari
target
modif
vaccin
design
tabl
also
known
nuclear
export
protein
nep
facilit
export
rnp
complex
nucleu
follow
assembl
sever
immunomodulatori
gene
identifi
influenza
includ
pax
tabl
sever
influenza
gene
known
interfer
normal
cell
activ
indirectli
impact
host
immun
function
pa
affect
host
cell
protein
synthesi
facilit
cap
snatch
host
cell
mrna
indirectli
suppress
host
antivir
respons
influenza
ion
channel
activ
known
activ
inflammasom
activ
nodlik
receptor
inhibit
activ
earli
influenza
infect
prevent
uncoat
replic
consequ
remain
key
target
antivir
subunit
chimer
vaccin
primari
immunomodulatori
protein
influenza
known
inhibit
tlr
signal
sever
mechan
disrupt
host
cell
ubiquitin
alter
host
cell
transcript
inhibit
activ
block
nuclear
transloc
sever
transcript
factor
suppress
host
translat
induc
signal
suppress
common
approach
gener
new
liveattenu
vaccin
candid
earli
studi
involv
either
delet
truncat
result
attenu
candid
still
provid
protect
mice
novel
mechan
modifi
level
protein
vaccin
design
recent
describ
use
codon
deoptim
codon
usag
deoptim
first
describ
mechan
viru
gene
modul
genet
stabl
mechan
reduc
polioviru
protein
synthesi
without
alter
protein
amino
acid
sequenc
approach
involv
substitut
least
use
codon
base
host
cell
codon
usag
bia
code
sequenc
viral
gene
approach
recent
employ
lower
gene
express
result
attenu
strain
protect
homolog
heterolog
challeng
pax
recent
identifi
shown
greatli
impact
host
respons
influenza
infect
discov
translat
result
altern
read
frame
segment
shown
induc
apoptosi
activ
inflammatori
pathway
enhanc
pathogenesi
secondari
bacteri
infect
pax
small
peptid
play
role
suppress
host
translat
identifi
key
regul
influenza
virul
regul
inflammatori
apoptot
pathway
host
infect
recent
delet
pax
shown
alter
pathogen
pandem
viru
pax
may
repres
new
intrigu
target
nextgener
vaccin
coronaviru
ongo
epidem
middl
east
respiratori
syndrom
mer
coronaviru
present
associ
mortal
rate
approxim
respect
epidem
highlight
need
effect
vaccin
therapeut
modern
advanc
studi
viru
applic
anim
model
provid
new
insight
pathogenesi
viru
repres
stabl
platform
test
liveattenu
candid
despit
high
clinic
econom
burden
remain
sever
challeng
continu
hinder
vaccin
develop
includ
potenti
rapid
revers
recombin
liveattenu
vaccin
candid
unclear
coronaviru
biolog
genom
coronavirus
rang
size
kb
repres
largest
known
rna
viru
genom
coronavirus
encod
nonstructur
protein
nsp
least
structur
protein
divers
set
accessori
protein
vari
form
function
strain
figur
function
mani
accessori
protein
coronavirus
remain
unclear
unknown
coronavirus
encod
mani
known
immunomodulatori
protein
membran
nucleocapsid
n
envelop
e
mani
accessori
protein
shown
play
key
role
host
immun
modul
tabl
addit
nsp
activ
involv
host
membran
modif
form
virusspecif
doubl
membran
vesicl
convolut
membran
structur
facilit
replic
complex
format
induc
membran
structur
play
key
role
evad
activ
host
tolllik
receptor
shield
doublestrand
rna
replic
though
convent
immunomodulatori
protein
recent
identifi
exonucleas
rna
proofread
activ
respons
confer
resist
viru
mutagenesi
nucleosideanalog
base
therapeut
develop
vaccin
candid
larg
focus
optim
express
spike
attach
glycoprotein
sever
novel
strategi
target
immunomodulatori
element
coronaviru
genom
develop
potenti
liveattenu
vaccin
delet
openread
frame
result
attenu
murin
coronaviru
howev
mutat
appreci
effect
virul
sarscov
howev
consider
energi
invest
gener
recombin
liveattenu
vaccin
target
e
coronaviru
envelop
e
protein
small
integr
membran
protein
well
studi
mani
identifi
function
includ
role
assembl
bud
host
cell
modif
littl
e
incorpor
coronaviru
virion
copi
per
virion
howev
high
concentr
e
detect
within
host
cell
viru
replic
despit
variou
function
e
dispens
viru
replic
sarscov
vaccin
contain
e
delet
gener
highli
attenu
hamster
exhibit
less
detect
viral
antigen
lung
histopatholog
lower
viral
titer
entir
new
direct
coronaviru
vaccin
design
focus
modifi
replic
fidel
viru
introduct
delet
exonucleas
domain
result
attenu
viru
increas
mutat
frequenc
attenu
vivo
surprisingli
retain
exonucleas
delet
serial
passag
discoveri
protect
natur
nucleosideanalog
stobart
respiratori
syncyti
viru
rsv
lead
caus
lower
respiratori
diseas
young
children
date
remain
rsv
vaccin
avail
present
monoclon
antibodi
prophylaxi
option
feasibl
popul
rsv
repres
signific
challeng
vaccin
design
sever
reason
first
highest
clinic
burden
associ
infant
age
immun
system
remain
compromis
second
viru
known
encod
sever
protein
facilit
innat
immun
evas
may
contribut
natur
infect
fail
induc
longlast
immun
prevent
reinfect
third
earli
effort
design
formalininactiv
rsv
vaccin
end
failur
result
enhanc
diseas
mortal
among
infant
contract
rsv
follow
vaccin
regrett
event
surround
earli
effort
hamper
vaccin
effort
lastli
remain
anim
model
fulli
recapitul
human
rsv
pathogenesi
rsv
vaccineenhanc
diseas
unfortun
tradit
attenu
method
dampen
viru
replic
yet
result
promis
balanc
safeti
immunogen
rsv
revers
genet
system
develop
group
gener
similar
system
reagent
permit
develop
nextgener
vaccin
integr
current
knowledg
rsv
pathogenesi
immun
evas
mechan
phylogenet
divers
immunogen
approxim
kb
genom
rsv
consist
gene
encod
protein
figur
genom
encod
least
four
establish
immunomodulatori
protein
nonstructur
protein
attach
glycoprotein
g
small
hydrophob
protein
sh
tabl
two
nonstructur
nonessenti
protein
shown
suppress
host
innat
immun
interferon
suppress
activ
prosurviv
pathway
antagon
apoptosi
express
high
quantiti
earli
infect
earli
effort
delet
protein
gener
vaccin
candid
result
either
overattenu
underattenu
candid
sitedirect
mutagenesi
key
function
residu
present
addit
challeng
littl
known
determin
protein
function
relev
rsv
like
mani
respiratori
virus
genet
instabl
although
mechan
remain
unclear
codondeoptim
success
appli
rsv
codon
deoptim
lower
detect
protein
level
subsequ
increas
protein
level
compar
wildtyp
rsv
approach
result
viru
attenu
compar
wildtyp
primari
human
cell
cultur
induc
slightli
higher
neutral
antibodi
data
suggest
modif
rsv
ns
protein
codondeoptim
may
repres
new
strategi
develop
nextgener
rsv
liveattenu
vaccin
candid
addit
rsv
nonstructur
protein
small
hydrophob
protein
sh
attach
glycoprotein
g
also
shown
play
sever
function
role
includ
modul
host
respons
rsv
sh
short
transmembran
protein
structur
similar
class
small
viroporin
shown
increas
membran
permeabl
express
bacteria
form
multimer
pore
complex
artifici
membran
function
sh
rsv
biolog
remain
larg
unclear
howev
shown
affect
apoptosi
inhibit
signal
delet
sh
protein
result
minor
attenu
mice
chimpanze
yet
incorpor
delet
appar
attenu
human
liveattenu
vaccin
candid
rsv
g
heavili
glycosyl
protein
shown
play
major
role
rsv
attach
engag
host
glycosaminoglycan
gag
coordin
fusion
f
glycoprotein
rsv
g
also
believ
help
facilit
cell
entri
infect
vivo
major
induc
antibodi
target
rsv
f
g
yet
rsv
g
antibodi
gener
far
less
effici
neutral
protect
f
antibodi
furthermor
rsv
g
exist
two
distinct
form
membranebound
surfac
expos
structur
shorter
secret
form
secret
rsv
g
function
immun
decoy
reduc
antibodi
efficaci
sever
studi
indic
g
also
modul
innat
immun
respons
structur
mimicri
inhibit
tlr
activ
howev
studi
involv
delet
rsv
g
gene
demonstr
g
protein
requir
rsv
infect
develop
rsv
vaccin
target
rsv
g
mostli
consist
express
whole
form
protein
compon
vaccin
chimer
strain
sendai
viru
piv
potenti
induc
protect
antibodi
howev
inabl
delet
g
without
attenu
viru
vaccin
candid
made
alter
immunomodulatori
activ
rsv
g
difficult
despit
associ
less
immunogen
rsv
f
rsv
g
vaccin
shown
promis
potenti
target
neutral
antibodi
one
studi
demonstr
use
g
subunit
vaccin
protect
immun
could
induc
rsv
rsv
b
subgroup
without
enhanc
pulmonari
patholog
due
larg
part
inabl
rsv
natur
infect
induc
longlast
protect
immun
develop
next
gener
liveattenu
rsv
vaccin
like
need
identifi
new
mechan
suppress
alter
activ
viral
immunomodulatori
gene
well
promot
protect
immunogen
antigen
measl
mump
virus
like
rsv
member
famili
paramyxovirida
envelop
negativestrand
rna
virus
associ
highli
contagi
diseas
may
fatal
yet
develop
measl
mump
vaccin
reduc
incid
measl
mump
worldwid
respect
sinc
introduct
vaccin
first
vaccin
measl
mump
passag
liveattenu
virus
develop
john
ender
mauric
hilleman
respect
current
mmr
vaccin
prepar
includ
liveattenu
strain
base
two
strain
well
liveattenu
strain
rubella
viru
howev
remain
need
improv
efficaci
measl
mump
vaccin
studi
shown
measl
vaccin
notic
level
vaccin
failur
children
receiv
two
dose
vaccin
fail
develop
protect
immun
histor
liveattenu
jeryl
lynn
strain
mump
vaccin
quit
safe
effect
last
year
howev
recent
outbreak
even
among
highli
vaccin
popul
prompt
question
whether
vaccin
improv
recent
reemerg
measl
mump
nation
histor
low
undetect
level
infect
inabl
erad
virus
promot
renew
effort
improv
efficaci
current
mmr
vaccin
prepar
measl
viru
kb
nonseg
negativesens
rna
genom
consist
gene
n
pvc
f
hn
l
encod
six
structur
protein
two
nonstructur
protein
figur
mump
viru
similar
genom
organ
encod
seven
gene
n
vp
f
sh
h
l
three
measl
protein
directli
associ
immunomodulatori
activ
infect
p
c
v
tabl
addit
nucleocapsid
n
protein
also
shown
measl
viru
indirectli
modifi
host
respons
inhibit
translat
capac
induc
apoptosi
numer
new
vaccin
prepar
made
improv
safeti
immunogen
h
f
n
protein
howev
novel
vaccin
strain
target
immunomodulatori
gene
larg
absent
much
work
current
done
understand
genet
differ
children
may
enhanc
suppress
immun
respons
measl
vaccin
data
combin
develop
revers
genet
approach
may
open
door
novel
liveattenu
vaccin
prepar
mump
two
primari
protein
involv
immunomodulatori
activ
v
sh
one
recent
mump
vaccin
candid
employ
dual
delet
v
sh
gene
result
attenu
immunogen
genet
stabil
develop
improv
measl
mump
next
gener
vaccin
like
focu
way
modifi
express
activ
gene
optim
develop
protect
immun
develop
vaccin
respiratori
virus
smallpox
measl
mump
rubella
recent
influenza
transform
landscap
medic
practic
contribut
substanti
near
doubl
life
expect
last
year
howev
method
classic
attenu
liveattenu
virus
passag
cold
adapt
directli
amen
preval
modern
respiratori
virus
rsv
remain
current
commerci
avail
vaccin
develop
safe
effect
vaccin
press
respiratori
challeng
envis
novel
approach
combin
advanc
revers
genet
detail
understand
biolog
viru
cornerston
next
gener
respiratori
viru
vaccin
common
strategi
enhanc
improv
host
respons
modifi
immunomodulatori
activ
viral
gene
discuss
sever
novel
strategi
provid
new
tool
tweak
adjust
function
immunomodulatori
element
respiratori
virus
vaccin
design
delet
gener
vaccin
base
genet
background
present
new
opportun
remov
virul
pathogen
element
respiratori
viru
system
optim
express
antigen
factor
modif
viral
codon
usag
repres
new
approach
rapidli
expand
mechan
suppress
viral
protein
express
without
delet
last
year
codonoptim
deoptim
success
employ
describ
earlier
polioviru
rsv
influenza
well
hepat
porcin
reproduct
respiratori
syndrom
viru
prrsv
lcmv
mechan
codondeoptim
protein
suppress
remain
larg
specul
believ
consist
combin
modifi
translat
kinet
alter
rna
secondari
structur
describ
earlier
nonstructur
protein
rsv
known
dispens
viral
replic
immunomodulatori
howev
delet
either
overor
underattenu
viru
vaccin
design
codondeoptim
like
expand
approach
develop
nextgener
vaccin
address
issu
alter
protein
function
genet
stabl
mechan
vaccin
remain
foundat
modern
advanc
public
health
expect
next
five
year
develop
nextgener
liveattenu
vaccin
focu
primarili
improv
antigen
display
optim
immunogen
pathogen
also
suppress
immunomodulatori
element
viru
limit
necessari
element
host
respons
establish
optim
protect
immun
